» Articles » PMID: 33425779

Intracellular Promotes the Proliferation of Colorectal Cancer Cells the MAPK/ERK Signaling Pathway

Overview
Date 2021 Jan 11
PMID 33425779
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

() is a keystone pathogen in periodontitis. However, several clinical studies have revealed an enrichment of in the stool samples and colorectal mucosa of colorectal cancer patients. Thus, the goal of this study was to determine whether can promote colorectal cancer progression . We established an acute infection model (24 h, multiplicity of infection =100) of invasion of colorectal cancer cells to study the alterations induced by in the proliferation and cell cycle of colorectal cancer cells. We observed that can adhere and invade host cells a few hours after infection. Once invaded, significantly promoted colorectal cancer cell proliferation, and the percentage of S phase cells was increased in the cell cycle assay. However, KDP136, a gingipain-deficient mutant of 33277, showed a decreased ability to promote colorectal cancer cell proliferation, indicating that gingipain is associated with colorectal cancer cell proliferation. Furthermore, we extracted RNA from colorectal cancer cells for high-throughput sequencing analysis and reconfirmed the results by quantitative polymerase chain reaction and western blot analyses. The results suggested that the MAPK/ERK signaling pathway is significantly activated by , while these changes were not observed for KDP136. In conclusion, can invade cells and promote the proliferation of colorectal cancer cells by activating the MAPK/ERK signaling pathway. Gingipain is an essential virulence factor in this interaction.

Citing Articles

promotes tumor progression via the Integrin α2/β1-PI3K-AKT-mTOR-C-myc signaling pathway in colorectal cancer.

Chen Y, Qin Y, Fan T, Qiu C, Zhang Y, Dai M Int J Biol Sci. 2025; 21(4):1497-1512.

PMID: 39990665 PMC: 11844286. DOI: 10.7150/ijbs.102742.


The interplay between gut bacteria and targeted therapies: implications for future cancer treatments.

He J, Chen Y, Zhao H, Li Y Mol Med. 2025; 31(1):58.

PMID: 39948481 PMC: 11827328. DOI: 10.1186/s10020-025-01108-6.


Tumor microbiome: roles in tumor initiation, progression, and therapy.

Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y Mol Biomed. 2025; 6(1):9.

PMID: 39921821 PMC: 11807048. DOI: 10.1186/s43556-025-00248-9.


Gut microbiota in cancer initiation, development and therapy.

Zhang R, Zhang X, Lau H, Yu J Sci China Life Sci. 2025; .

PMID: 39821827 DOI: 10.1007/s11427-024-2831-x.


Intratumoral microbiota in colorectal cancer: focus on specific distribution and potential mechanisms.

Long J, Wang J, Xiao C, You F, Jiang Y, Li X Cell Commun Signal. 2024; 22(1):455.

PMID: 39327582 PMC: 11426098. DOI: 10.1186/s12964-024-01831-3.


References
1.
Rubinstein M, Wang X, Liu W, Hao Y, Cai G, Han Y . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206. PMC: 3770529. DOI: 10.1016/j.chom.2013.07.012. View

2.
Baxter D, Perry S, Hill T, Kok W, Zaccai N, Brady R . Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun. ACS Chem Biol. 2017; 12(8):2051-2061. DOI: 10.1021/acschembio.7b00303. View

3.
Crawford H, Matrisian L . Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein. 1996; 49(1-3):20-37. DOI: 10.1159/000468614. View

4.
Al-Hebshi N, Nasher A, Maryoud M, Homeida H, Chen T, Idris A . Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Sci Rep. 2017; 7(1):1834. PMC: 5431832. DOI: 10.1038/s41598-017-02079-3. View

5.
Polak D, Wilensky A, Shapira L, Halabi A, Goldstein D, Weiss E . Mouse model of experimental periodontitis induced by Porphyromonas gingivalis/Fusobacterium nucleatum infection: bone loss and host response. J Clin Periodontol. 2009; 36(5):406-10. DOI: 10.1111/j.1600-051X.2009.01393.x. View